Drug Trial Radar · NCT00739453
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Oct 23, 2008
Primary completion
Mar 3, 2012
Study completion Mar 3, 2012
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
Conditions
- Advanced Solid Tumors
Interventions
OSI-906Drug
administered orally
erlotinibDrug
administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinibTime frame: 21 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
University of Colorado Health Science Center
Aurora, Colorado
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Hudson-Webber Cancer Research Center, Karmanos Cancer Institute
Detroit, Michigan
University of Oxford Department of Medical Oncology
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.